Prokidney Corp PROK

$1.38 -0.04 (-2.48%)

Valuation

Market cap
426,275,000
Revenue TTM
$890,000
Net income TTM
$-68,990,000
PE ratio
0.00
Forward PE
—
Profit margin
-7,751.69%
Debt to equity
0.00

Trading

Volume
450,783
Avg volume
1,375,356
Day's range
$1.38 – $1.44
Shares out
302,323,000
Stochastic %K
28%
Beta
1.77
Analysts
Sell
Price target
$6.12

Price

Company profile

ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserv...

Show more

ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Industry
Biotechnology
Sector
Healthcare
Phone
336 999 7019
Website
https://prokidney.com
Address
2000 Frontis Plaza Boulevard, Suite 250, Winston-Salem, United States

Latest news

Stocktwits

Merlintrader Oct 25, 5:55 PM
$PROK closed at $1.41, below the 50-day EMA ($1.62) and the 200-day ($1.92), near the low of its 20-day range ($1.30-$1.76). Daily RSI 39. Interactive chart at JC Just Charts: https://justcharts.merlintrader.com/#PROK Not investment advice.
0 replies
Merlintrader Oct 22, 8:41 PM
$PROK Latest company news, Oct 22, 2026: ProKidney hosts a virtual KOL event on October 27 at 10:30 a.m. ET on the mechanism-of-action research presented at Kidney Week, plus a corporate update. ProKidney ($PROK) Stock Hub: What Will Eight Kidney Week 2026 Abstracts Add Before the Q2 2027 PROACT 1 Readout? https://www.merlintrader.com/prokidney-stock-hub/ Chart (daily): price around 1.43, below the 50-day (about 1.66) and 200-day (about 1.85) moving averages. Since March it has moved inside a falling channel; the upper line is now near 1.95, and the recent lows sit around 1.35-1.40. Not investment advice.
0 replies
Strizzball Oct 21, 1:33 AM
$PROK https://www.hhs.gov/press-room/hhs-launches-kidney-care-national-plan.html
0 replies
kingrichard1234 Oct 19, 6:13 PM
$PROK early results are showing great promise. This is going to help so many people. I am in for the long haul.
0 replies
Neil_Armstrong Oct 19, 12:34 PM
$PROK I bought some on Friday. Looking forward to making tons of money with yall 🤞🤞💵💵💵
0 replies
Merlintrader Oct 17, 6:54 PM
📅 CATALYST REMINDER | $PROK October 23, 2026 — Phase 2 Clinical Data ProKidney will present pooled Phase 2 rilparencel safety and efficacy findings at ASN Kidney Week. More details in our hub. #PROK #Biotech #KidneyWeek
1 replies
Nataina Oct 14, 7:37 PM
$PROK what is going on here why people sell ! Wait 2-4 m you ll double at least
0 replies
Biohacker Oct 9, 1:24 PM
$PROK https://www.asn-online.org/education/kidneyweek/2026/program-abstract.aspx?controlId=4556254&utm_source=chatgpt.com
0 replies